Full Press Release Details
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer.
ALXO
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
Key Takeaway: ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer